Stocks Health care HALO
NASDAQ · Health careHalozyme Therapeutics, Inc. (HALO)
Halozyme Therapeutics, Inc. brought in $1.8B of revenue over the twelve months to September 30, 2026, up 45.0% from a year earlier. Net income was $485.4M, a net margin of 26.9%. Operating cash flow minus capital spending left $644.6M of free cash flow in fiscal 2025. At September 30, 2026 it held $1B in cash against $3.3B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Halozyme Therapeutics, Inc.
- Net worth
- Halozyme Therapeutics, Inc. has a market value (market cap) of $11.7B at the latest share price, and shareholders' equity of -$55.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.4B (+37.6% year on year), with net income of $316.9M. Over the 12 months to September 30, 2026: revenue $1.8B, net income $485.4M.
- Cash flow
- In fiscal 2025 operations brought in $651.6M of cash; after $7M of capital spending, free cash flow was $644.6M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Halozyme Therapeutics, Inc.'s next report is expected around January 27, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Halozyme Therapeutics, Inc. does
Halozyme Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker HALO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.4B | $316.9M | $2.56 | $644.6M |
| 2024 | $1B | $444.1M | $3.43 | $468.4M |
| 2023 | $829.3M | $281.6M | $2.10 | $373.3M |
| 2022 | $660.1M | $202.1M | $1.44 | $235.3M |
| 2021 | $443.3M | $402.7M | $2.74 | $298M |
| 2020 | $267.6M | $129.1M | $0.91 | $53M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where HALO ranks in Health care
Latest SEC filings
What Halozyme Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 39% to $493M versus the same quarter last year; diluted EPS $2.01 versus $1.43.
- November 5, 2026
- September 30, 2026Executive or director change8-KJames Daly has been elected to the Board of Directors of Halozyme Therapeutics.
- September 22, 2026Material agreement8-KHalozyme completed the sale of $1,500.0 million in convertible senior notes due 2033 and funded debt repurchases and capped call transactions.
- September 18, 2026Other event 8-K
- September 16, 2026Other event 8-K
- August 18, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 48% to $481M versus the same quarter last year; diluted EPS $1.90 versus $1.33.
- August 6, 2026
- July 2, 2026
What is HALO worth? A DCF from its reported cash flow
Insider trades
What the people running Halozyme Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $21.9M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 8, 2026 | Torley HelenPRESIDENT AND CEO, Director | Exercised options | 20,000 | $368.2K |
| October 8, 2026 | Torley HelenPRESIDENT AND CEO, Director | Soldpre-planned (10b5-1) | 4,810 | $520.3K |
| October 8, 2026 | Torley HelenPRESIDENT AND CEO, Director | Soldpre-planned (10b5-1) | 3,090 | $336.5K |
| October 8, 2026 | Torley HelenPRESIDENT AND CEO, Director | Soldpre-planned (10b5-1) | 11,900 | $1.3M |
| October 8, 2026 | Torley HelenPRESIDENT AND CEO, Director | Soldpre-planned (10b5-1) | 200 | $22.1K |
| October 7, 2026 | Torley HelenPRESIDENT AND CEO, Director | Exercised options | 20,000 | $368.2K |
| October 7, 2026 | Torley HelenPRESIDENT AND CEO, Director | Soldpre-planned (10b5-1) | 8,600 | $954.9K |
| October 7, 2026 | Torley HelenPRESIDENT AND CEO, Director | Soldpre-planned (10b5-1) | 10,300 | $1.2M |
Who owns HALO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Vanguard Capital Management13G, passive | 5.21% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 668 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 13,271,095 | +6,042 |
| Vanguard Capital Management LLC | 5,351,312 | +80,094 |
| Vanguard Portfolio Management LLC | 5,299,008 | +49,802 |
| State Street Corp | 5,179,434 | +241,580 |
| Invesco Ltd. | 3,177,997 | -834,497 |
| Morgan Stanley | 2,832,594 | +270,285 |
| Boston Partners | 2,773,568 | +89,885 |
| Bank of America Corp | 2,740,561 | -172,548 |
| Geode Capital Management, LLC | 2,519,951 | +14,165 |
| William Blair Investment Management, LLC | 2,511,050 | -14,925 |
| Snyder Capital Management L P | 2,396,101 | +73,024 |
| Dimensional Fund Advisors LP | 2,089,567 | +9,740 |
| D. E. Shaw & Co., Inc. | 2,006,479 | +137,771 |
| Assenagon Asset Management S.A. | 1,995,286 | +1,973,964 |
| Los Angeles Capital Management LLC | 1,938,035 | +1,248,120 |
| Royal London Asset Management Ltd | 1,810,815 | +200,262 |
| Arrowstreet Capital, Limited Partnership | 1,704,623 | -213,526 |
| Two Sigma Investments, LP | 1,653,285 | +68,324 |
| UBS Group AG | 1,492,224 | +578,221 |
| Fuller & Thaler Asset Management, Inc. | 1,491,004 | +25,721 |
Insiders
13 insiders reported holding 1,044,530 shares in total, about $107.6M at the last price.
| Holder | Shares |
|---|---|
| Torley HelenPRESIDENT AND CEO, Director | 767,780 |
| Posard Matthew L.Director | 53,609 |
| Snyder Mark HowardSVP, CHIEF LEGAL OFFICER | 49,929 |
| Connaughton BernadetteDirector | 40,418 |
| LaBrosse NicoleSVP, CHIEF FINANCIAL OFFICER | 38,494 |
| Henderson Jeffrey WilliamDirector | 36,572 |
| Duncan Barbara GayleDirector | 23,715 |
| Krishnan MaheshDirector | 14,462 |
| Caudill CortneySVP, CHIEF OPERATING OFFICER | 7,055 |
| Lang James PaulDirector | 5,574 |
Questions about HALO
What does Halozyme Therapeutics, Inc. do?
Halozyme Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as HALO. Its shares trade on NASDAQ under the ticker HALO.
What is Halozyme Therapeutics, Inc.'s net worth?
Halozyme Therapeutics, Inc. has a market value (market cap) of $11.7B at the latest share price, and shareholders' equity of -$55.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Halozyme Therapeutics, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $485.4M on revenue of $1.8B, a net margin of 26.9%.
How much revenue does Halozyme Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Halozyme Therapeutics, Inc. reported revenue of $1.8B. That is 45.0% more than a year earlier.
When did Halozyme Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Halozyme Therapeutics, Inc.'s next earnings report?
Halozyme Therapeutics, Inc.'s next report is expected around January 27, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare HALO with
Follow HALO
Get an email when Halozyme Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Halozyme Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.